MEDP Stock Forecast: Medpace Holdings, Inc. Price Predictions for 2026-2027
The 14 Wall Street analysts covering Medpace Holdings, Inc. hold a median 12-month price target of $675 — +10.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 93 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Medpace Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (97): The business earns solid, repeatable profits on what it owns.
Accruals (63): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
MEDP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MEDP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +10.6% from it.
Of the 20 most recent actions, 17 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Oct 2026 | BMO Capital | Maintains | Market Perform | $600 → $670 |
| 23 Oct 2026 | Barclays | Maintains | Equal-Weight | $625 → $675 |
| 23 Oct 2026 | TD Cowen | Maintains | Hold | $492 → $673 |
| 23 Oct 2026 | Truist Securities | Maintains | Hold | $609 → $633 |
| 23 Oct 2026 | UBS | Maintains | Neutral | $673 → $700 |
| 7 Oct 2026 | Barclays | Maintains | Equal-Weight | $600 → $625 |
| 7 Oct 2026 | Mizuho | Maintains | Outperform | $665 → $700 |
| 30 Sept 2026 | UBS | Upgrade | Neutral | $405 → $673 |
| 24 July 2026 | Baird | Maintains | Neutral | $547 → $624 |
| 24 July 2026 | BMO Capital | Maintains | Market Perform | $400 → $600 |
| 24 July 2026 | Mizuho | Maintains | Outperform | $586 → $665 |
| 24 July 2026 | RBC Capital | Maintains | Outperform | $484 → $692 |
| 24 July 2026 | TD Cowen | Maintains | Hold | $419 → $492 |
| 24 July 2026 | Truist Securities | Maintains | Hold | $462 → $609 |
| 13 July 2026 | Mizuho | Maintains | Outperform | $495 → $586 |
| 8 July 2026 | Baird | Downgrade | Neutral | $477 → $547 |
| 7 July 2026 | Jefferies | Downgrade | Hold | $490 → $515 |
| 24 Apr 2026 | Baird | Maintains | Outperform | — |
| 24 Apr 2026 | Barclays | Maintains | Equal-Weight | — |
| 24 Apr 2026 | BMO Capital | Maintains | Market Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MEDP.
This page is one stock. Monday covers all of them.
MEDP appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
MEDP vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Medpace Holdings, Inc. returned +4.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
MEDP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 33.9×
- Price / sales
- 6.0×
- Price / book
- 29.2×
- EV / EBITDA
- 26.1×
Cheaper than 25% of US stocks
Cheaper than 18% of US stocks
Cheaper than 2% of US stocks
Cheaper than 14% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- 23.7%
- Gross margin
- 28.5%
- Operating margin
- 21.4%
- Net margin
- 18.2%
Higher than 62% of US stocks
Higher than 32% of US stocks
Higher than 81% of US stocks
Higher than 79% of US stocks
- Return on equity
- 117.9%
- Return on assets
- 18.7%
- Dividend yield
- —
Higher than 97% of US stocks
Higher than 98% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Medpace Holdings, Inc. has a market value of $17.1B and an enterprise value of $16.5B.
Revenue in the twelve months to 30 June 2026: $2.8B. The latest quarter grew 17.2% year on year.
Net income over the same four quarters: $491.5M, a 17.7% net margin.
Diluted earnings per share, trailing twelve months: $17.06.
Free cash flow in the twelve months to 30 June 2026: $706.7M.
Medpace Holdings, Inc. spent $299.3M on share buybacks in the twelve months to 30 June 2026.
Trailing P/E: 33.9×; forward P/E: 30.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Medpace Holdings, Inc. employs 6,600 people — $422K of revenue per employee.
Data provided by Twelve Data
MEDP and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at MEDP’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Medpace Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about MEDP
What is the MEDP stock price forecast for 2026-2027?
The 14 Wall Street analysts covering Medpace Holdings, Inc. have a median 12-month price target of $675, with estimates ranging from $370 to $730. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MEDP stock a buy right now?
Of the 14 analysts covering Medpace Holdings, Inc., 2 rate it a Buy, 11 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Medpace Holdings, Inc. 93 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MEDP?
As at 21 Nov 2026, Medpace Holdings, Inc. ranks 93 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Quality (97 of 100).
Will MEDP stock go up?
No one can know that. What the data says: the median 12-month target from 14 analysts implies +10.6% from the last close, and Ticker Nerd's factor model ranks Medpace Holdings, Inc. 93 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MEDP stock forecast for 2030?
No analyst covering Medpace Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MEDP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $370 to $730 over the next 12 months.
How has MEDP stock performed over the past year?
Medpace Holdings, Inc. returned +4.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Medpace Holdings, Inc. do?
Medpace Holdings, Inc. is a global clinical research organization that provides outsourced clinical development services for biotechnology, pharmaceutical, and medical device companies. Medpace supports the full clinical trial lifecycle, from Phase I through Phase IV, with services that include study design, project management, clinical monitoring, regulatory affairs, data management, biostatistics, medical writing, pharmacovigilance, and post-marketing support.
About Medpace Holdings, Inc.
Medpace Holdings, Inc. is a global clinical research organization that provides outsourced clinical development services for biotechnology, pharmaceutical, and medical device companies. Medpace supports the full clinical trial lifecycle, from Phase I through Phase IV, with services that include study design, project management, clinical monitoring, regulatory affairs, data management, biostatistics, medical writing, pharmacovigilance, and post-marketing support. The company also offers specialized laboratory and trial support capabilities such as central laboratory services, bioanalytical testing, imaging core laboratory services, and cardiac safety assessments. Medpace serves clients across North America, Europe, Asia, South America, Africa, and Australia, playing a central role in helping sponsors run complex clinical programs and advance medical products through development.
CEO Dr. August James Troendle M.D. · 6,600 employees · United States · https://www.medpace.com